outperformance. It also includes our commitment to clear communication. These are the principles we used when issuing our initial 2026 guidance at the end of last year and are what you can expect as we move forward. Today, we are reaffirming our guidance for full year 2026 revenue of at least $400 billion, as well as our results as we closed out 2025, and by our momentum as we start this year. underlying our guidance. We are also pleased with how we completed the Medicare Advantage annual enrollment period with our enrollment coming in modestly down, which was in line with our expectations. from certain payments that shifted from 2026 into late 2025, as well as the persistence of underlying across 2025 and 2026 has increased by over $1.5 billion. We continue to expect a roughly 55/45 split of earnings additional details on the components of our 2026 guidance on our Investor Relations website. Overall, 2025 was a strong year at CVS Health. We successfully navigated unexpected challenges and delivered building significant momentum into 2026. earnings opportunity ahead of us. We see a clear path to an incredible amount of shareholder value and are With that, we will now open the call to your questions. Operator?